Liver Cirrhosis Market Report 2026

The liver cirrhosis market size has grown strongly in recent years. It will grow from $1.99 billion in 2025 to $2.15 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to chronic alcohol consumption patterns, widespread hepatitis b and c infections, limited early detection of liver damage, rising incidence of fatty liver disease, historical lack of curative treatment options.

The liver cirrhosis market size is expected to see strong growth in the next few years. It will grow to $2.88 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing burden of NASH and metabolic syndrome, growing awareness of liver health, expanding access to diagnostic testing, rising demand for advanced liver care, increased healthcare spending on chronic diseases. Major trends in the forecast period include rising prevalence of chronic liver diseases, growing focus on early diagnosis and disease monitoring, increasing demand for long-term disease management, expansion of supportive and symptom-based therapies, rising need for specialized hepatology care.

The rise in alcohol consumption is anticipated to drive the growth of the liver cirrhosis market in the coming years. Alcohol consumption refers to the intake of alcoholic beverages, typically measured in terms of frequency and quantity. People are increasingly consuming alcohol as it helps them relax from daily stress, fosters social interactions during gatherings, and enhances moments of leisure, while also being widely advertised in media and more accessible in various environments. Treatment for liver cirrhosis in patients with excessive alcohol intake focuses on managing liver damage through abstinence, medications, and supportive care, while addressing alcohol dependence through counseling and rehabilitation. For example, in December 2024, according to the Bureau of Labor Statistics, a US government agency, in 2023, U.S. households spent an average of $294 on alcoholic beverages consumed at home and $343 on those consumed outside. Hence, the increase in alcohol consumption contributes to the growth of the liver cirrhosis market.

Key players in the liver cirrhosis market are concentrating on advancements in treatment options, such as the development of active implantable medical devices, to enhance patient outcomes and broaden therapeutic opportunities. Active implantable medical devices are electronically powered implants designed to monitor, support, or improve organ function within the body. For instance, in December 2024, Sequana Medical NV, a Belgium-based medical device company, received U.S. FDA approval for its alfapump system, marking the first active implantable medical device in the U.S. for managing recurrent or refractory ascites caused by liver cirrhosis. This innovative technology provides a continuous, automated solution for fluid management by transferring excess abdominal fluid to the bladder, significantly reducing reliance on invasive therapeutic paracentesis. Alfapump represents a significant advancement in improving patient outcomes and quality of life, with an addressable market of around 70,000 patients in the United States.

In September 2023, Galectin Therapeutics, a U.S.-based company offering liver cirrhosis treatments, partnered with HistoIndex to present findings on liver cirrhosis at the 9th Paris NASH meeting. Through this collaboration, Galectin Therapeutics and HistoIndex aim to utilize artificial intelligence to enhance the analysis of liver cirrhosis histology, providing deeper insights into disease progression and treatment efficacy. HistoIndex is a Singapore-based medical technology company.

Major companies operating in the liver cirrhosis market are F Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens Healthineers AG, GE HealthCare Technologies Inc., Fujifilm Holdings Corporation, Canon Medical Systems Corporation, Koninklijke Philips N.V., Samsung Medison Co. Ltd., Mindray Medical International Limited, Boston Scientific Corporation, Olympus Corporation, Echosens SA, Hologic Inc., Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., bioMérieux SA, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Perspectum Diagnostics Ltd., Owlstone Medical Ltd.

North America was the largest region in the liver cirrhosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver cirrhosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liver cirrhosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the liver cirrhosis market by increasing costs related to imported diagnostic equipment, pharmaceuticals, and hospital-grade medical supplies used in disease management. These impacts are more pronounced in advanced treatment and diagnostic segments, particularly in regions such as asia-pacific and europe that rely on global medical supply chains. Hospitals and specialty clinics face higher operational and procurement costs due to tariff pressures. However, tariffs have also encouraged local production of medical supplies, regional sourcing strategies, and stronger healthcare infrastructure resilience.

The liver cirrhosis market research report is one of a series of new reports that provides liver cirrhosis market statistics, including liver cirrhosis industry global market size, regional shares, competitors with a liver cirrhosis market share, detailed liver cirrhosis market segments, market trends and opportunities, and any further data you may need to thrive in the liver cirrhosis industry. This liver cirrhosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Liver cirrhosis is a progressive condition in which healthy liver tissue is gradually replaced by scar tissue, reducing the liver’s ability to function effectively. This disease develops due to prolonged liver damage caused by factors such as chronic alcohol use, viral hepatitis, or fatty liver disease.

The primary types of liver cirrhosis include alcoholic cirrhosis, atrophic cirrhosis, biliary cirrhosis, cardiac cirrhosis, and cryptogenic cirrhosis. Alcoholic cirrhosis is a severe liver disorder resulting from long-term excessive alcohol consumption, causing liver scarring, impaired function, and possible liver failure. Various treatment options are available, including antibiotics, immunosuppressants, and other therapies. The main end users are hospitals, specialty clinics, ambulatory surgical centers, academic and research institutes, and other healthcare providers.

The liver cirrhosis market consists of revenues earned by entities providing services such as diagnosis and screening services, medical treatment, management services, and patient support. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cirrhosis market also includes sales of medications, diagnostic tools, medical devices, and therapeutic treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.